纖溶酶原激活物抑制因子1(PAI1)活性蛋白
Active Plasminogen Activator Inhibitor 1 (PAI1)
SERPINE1; PLANH1; Serpin Peptidase Inhibitor Clade E Member 1; Nexin,Plasminogen Activator Inhibitor Type 1 Serpin E1; Endothelial plasminogen activator inhibitor
- 編號APA532Hu61
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 緩沖液成份磷酸鹽緩沖液（pH7.4，含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.）
- 性狀凍干粉
- 純度> 95%
- 等電點7.5
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1642 ¥ 4104 ¥ 8208 ¥ 24624 ¥ 61560
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
SDS-PAGE圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
活性實驗
Plasminogen Activator Inhibitor 1 (PAI1) is a member of the Serpin superfamily of serine protease inhibitors, Serpin E1/PAI 1 is the principal inhibitor of urokinase type plasminogen activator (uPA) and tissue type PA. As important regulators of extracellular matrix remodeling, uPA and PAI 1 play a major role in many processes such as angiogenesis, tumor invasion and obesity. Besides, Vitronectin (VTN) has been identified as an interactor of PAI1, thus a binding ELISA assay was conducted to detect the interaction of recombinant human PAI1 and recombinant human VTN. Briefly, PAI1 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to VTN-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-PAI1 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50μL stop solution to the wells and read at 450nm immediately. The binding activity of PAI1 and VTN was shown in Figure 1, and this effect was in a dose dependent manner, the EC50 was approximately 4.47 ug/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當?shù)臈l件下存儲，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA532Hu02 | 纖溶酶原激活物抑制因子1(PAI1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| EPA532Hu61 | 纖溶酶原激活物抑制因子1(PAI1)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA532Hu01 | 纖溶酶原激活物抑制因子1(PAI1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA532Hu61 | 纖溶酶原激活物抑制因子1(PAI1)活性蛋白 | Cell?culture;?Activity?Assays. |
| PAA532Hu01 | 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA532Hu02 | 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA532Hu71 | 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| LAA532Hu81 | 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
| MAA532Hu22 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC/IF |
| MAA532Hu24 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA532Hu27 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA532Hu29 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA532Hu25 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA532Hu21 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA532Hu26 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA532Hu28 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA532Hu23 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | WB; IHC |
| FAA532Hu04 | 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | Flow cytometry. |
| FAA532Hu02 | 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | Flow cytometry. |
| FAA532Hu06 | 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | Flow cytometry. |
| FAA532Hu08 | 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 | Flow cytometry. |
| LAA532Hu74 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體(生物素標記) | WB; IHC; ICC. |
| LAA532Hu76 | 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體(生物素標記) | WB; IHC; ICC. |
| MEA532Hu | 纖溶酶原激活物抑制因子1(PAI1)檢測試劑盒(酶聯(lián)免疫吸附試驗法,小樣本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SEA532Hu | 纖溶酶原激活物抑制因子1(PAI1)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA532Hu | 纖溶酶原激活物抑制因子1(PAI1)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA532Hu | 纖溶酶原激活物抑制因子1(PAI1)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| PSA532Hu01 | 纖溶酶原激活物抑制因子1(PAI1)抗體對 | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
| KSA532Hu01 | 纖溶酶原激活物抑制因子1(PAI1)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| Breast Cancer Research and Treatment | Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice [SpringerLink: f3w831267267p277] |
| Clin Appl Thromb Hemost. | Is There Any Association Between Thrombosis and Tissue Factor Pathway Inhibitor Levels in Patients With Vitamin D Deficiency? [Pubmed: 24203351] |
| Molecular Nutrition & Food Research | Trans‐fatty acid promotes thrombus formation in mice by aggravating antithrombogenic endothelial functions via Toll‐like receptors [PubMed: 25546502] |
| Archives of Physiology and Biochemistry | Activation of cardiac renin–angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorder [Pubmed:26934364] |
| Naunyn-Schmiedeberg's Archives of Pharmacology | Combined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expression [pubmed:27447455] |
| Environmental toxicology and pharmacology | Combined oral contraceptive and nitric oxide synthesis inhibition synergistically causes cardiac hypertrophy and exacerbates insulin resistance in female rats. [pubmed:28376377] |
| Annals of Clinical & Laboratory Science | Alteration of Hemostatic Parameters in Patients with Different Levels of Subclinical Hypothyroidism and the Effect of L-thyroxine Treatment [pubmed:28249913] |
| Pharmacological reports | Anti-inflammatory and antithrombotic effects of nicotine exposure in oral contraceptive-induced insulin resistance are glucocorticoid-independent [pubmed:28349880] |
| Haematologica | Cytoprotective and pro-angiogenic functions of thrombomodulin are preserved in the C loop of the fifth epidermal growth factor-like domain [Pubmed:29903766] |
| Biomedicine & Pharmacotherapy | Puerarin prevents vascular endothelial injury through suppression of NF-κB activation in LPS-challenged human umbilical vein endothelial cells [Pubmed:29775893] |
| Archives of?Physical?Medicine?and Rehabilitation | Impact of Regular Physical Activity on Adipocytokines and Cardiovascular Characteristics in Spinal Cord–Injured Subjects [Pubmed:29548578] |
| Marine Drugs | Anticoagulant and Antithrombotic Properties in Vitro and in Vivo of a Novel Sulfated Polysaccharide from Marine Green Alga Monostroma nitidum [Pubmed: 31027312] |
| Experimental and Therapeutic Medicine | IKKβ regulates the expression of coagulation and fibrinolysis factors through the NF?κB canonical pathway in LPS?stimulated alveolar epithelial cells type II [Pubmed: 31572531] |
| Phytomedicine | Sodium aescinate significantly suppress postoperative peritoneal adhesion by inhibiting the RhoA/ROCK signaling pathway [Pubmed: 32120245] |
| Sci Rep | Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis [Pubmed:35013379] |
| Phytomedicine | Multi-omics analysis reveals the mechanisms of action and therapeutic regimens of traditional Chinese medicine, Bufei Jianpi granules: Implication for COPD drug?… [Pubmed:35121390] |
